Enveda raises $311 million to move nature-based AI drugs into trials

In short: Enveda raised $311 million to help bring more drug ideas found in nature, and picked with AI, into human clinical trials.

What happened

Enveda, a biotech startup, announced a $311 million Series E funding round. The round values the company at about $2 billion, according to TechCrunch.

Catalio Capital Management led the investment, with participation from Iconiq and other investors. TechCrunch reported that this valuation is about double what Enveda reached 12 months ago.

Enveda’s focus is finding potential medicines in plants and microbes, instead of building them from scratch in a lab. The company uses AI, meaning software that looks for patterns in large amounts of data, to speed up the search. You can think of it like using a fast search tool to sort through a huge library of natural chemicals and flag the ones that look most promising.

The company was founded in 2019 by Viswa Colluru, a former early employee at Recursion Pharmaceuticals. Enveda is part of a growing group of companies trying to turn AI-picked drug candidates into real medicines.

Enveda is currently testing several drugs in people. These include one aimed at severe skin conditions, and another designed to help people maintain weight loss after they stop taking GLP-1 drugs (a popular class of medicines used for diabetes and weight loss).

Why it matters

AI has not yet produced a drug that has been approved by the US Food and Drug Administration, so moving candidates into human testing is a key step. For patients, the practical question is whether this approach can lead to safe treatments faster, or uncover medicines that would be hard to find with traditional lab work.

Source: TechCrunch AI